The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis
| Autor: | C. Blank, Karijn P M Suijkerbuijk, Karlijn de Joode, Adriana Hepner, Céleste Lebbé, Yanina J L Jansen, Elisabeth G.E. de Vries, Andrew Haydon, Claudia Trojaniello, Lucy Storey, Paul Lorigan, Lauren Julia Brown, Alexander M. Menzies, Joanna Mangana, Astrid Aplonia Maria Van Der Veldt, Shahneen Sandhu, Bart Neyns, Douglas B. Johnson, Ellen Kapiteijn, Lisa Zimmer, Matteo S. Carlino, Georgina V. Long, Alison Weppler, Anne M. Hendriks, Harm van Tinteren, Judith M. Versluis, Mathilde Jalving, Victoria Atkinson, Prachi Bhave, Paolo A. Ascierto, Clara Allayous |
|---|---|
| Přispěvatelé: | Surgery, Faculty of Medicine and Pharmacy, Clinical sciences, Medical Oncology, Laboratory for Medical and Molecular Oncology, Radiology & Nuclear Medicine, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Targeted Gynaecologic Oncology (TARGON) |
| Rok vydání: | 2021 |
| Předmět: |
Male
0301 basic medicine Oncology Cancer Research Skin Neoplasms Time Factors medicine.medical_treatment Medizin Systemic therapy 0302 clinical medicine Stable Disease Risk Factors METASTATIC MELANOMA Immune Checkpoint Inhibitors Melanoma OUTCOMES Manchester Cancer Research Centre Progression-free survival Radiotherapy Dosage Middle Aged Progression-Free Survival Europe 030220 oncology & carcinogenesis Disease Progression SURVIVAL Female Immune checkpoint inhibition medicine.symptom medicine.medical_specialty Oligoprogression Metastatic melanoma Lesion Solitary progression 03 medical and health sciences SDG 3 - Good Health and Well-being Internal medicine medicine Humans IMMUNOTHERAPY Aged Neoplasm Staging Retrospective Studies business.industry ResearchInstitutes_Networks_Beacons/mcrc Australia Metastasectomy Immunotherapy medicine.disease United States Immune checkpoint Treatment METASTASES 030104 developmental biology business |
| Zdroj: | European Journal of Cancer, 151, 72-83. Elsevier Ltd. European Journal of Cancer, 151, 72-83. ELSEVIER SCI LTD Versluis, J M, Hendriks, A M, Weppler, A M, Brown, L J, de Joode, K, Suijkerbuijk, K P M, Zimmer, L, Kapiteijn, E W, Allayous, C, Johnson, D B, Hepner, A, Mangana, J, Bhave, P, Jansen, Y J L, Trojaniello, C, Atkinson, V, Storey, L, Lorigan, P, Ascierto, P A, Neyns, B, Haydon, A, Menzies, A M, Long, G V, Lebbe, C, van der Veldt, A A M, Carlino, M S, Sandhu, S, van Tinteren, H, de Vries, E G E, Blank, C U & Jalving, M 2021, ' The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis ', European Journal of Cancer, vol. 151, pp. 72-83 . https://doi.org/10.1016/j.ejca.2021.04.003 European Journal of Cancer, 151, 72-83. ELSEVIER |
| ISSN: | 0959-8049 |
| Popis: | Introduction: In patients with metastatic melanoma, progression of a single tumour lesion (solitary progression) after response to immune checkpoint inhibition (ICI) is increasingly treated with local therapy. We evaluated the role of local therapy for solitary progression in melanoma.Patients and methods: Patients with metastatic melanoma treated with ICI between 2010 and 2019 with solitary progression as first progressive event were included from 17 centres in 9 countries. Follow-up and survival are reported from ICI initiation.Results: We identified 294 patients with solitary progression after stable disease in 15%, partial response in 55% and complete response in 30%. The median follow-up was 43 months; the median time to solitary progression was 13 months, and the median time to subsequent progression after treatment of solitary progression (TTSP) was 33 months. The estimated 3-year overall survival (OS) was 79%; median OS was not reached. Treatment consisted of systemic therapy (18%), local therapy (36%), both combined (42%) or active surveillance (4%). In 44% of patients treated for solitary progression, no subsequent progression occurred. For solitary progression during ICI (n = 143), the median TTSP was 29 months. Both TTSP and OS were similar for local therapy, ICI continuation and both combined. For solitary progression post ICI (n = 151), the median TTSP was 35 months. TTSP was higher for ICI recommencement plus local therapy than local therapy or ICI recommencement alone (p = 0.006), without OS differences.Conclusion: Almost half of patients with melanoma treated for solitary progression after initial response to ICI had no subsequent progression. This study suggests that local therapy can benefit patients and is associated with favourable long-term outcomes. & ordf;2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect